石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group's Furosemide has obtained the approval for registration from the National Medical Products Administration of China (the "NMPA") to become bulk drug for the preparations on the market. As stated in the Company's announcements dated 30 June 2025 and 27 December 2024 respectively, the Group has obtained the approvals for drug production and registration for Furosemide Tablet and Furosemide Injection from the NMPA.

Furosemide is mainly used for the treatment of various diseases with edema, hypertension, hyperkalemia and hypercalcemia, dilutional hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and acute drug poisoning (such as barbiturate poisoning), and for the prevention of acute kidney failure.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 21 April 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.